Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Nonmyeloablative allogeneic stem cell transplantation for acute leukemia.

Ginna G Laport¹

¹Division of Bone Marrow Transplantation, Stanford University Medical Center, 300 Pasteur Drive, Room H3249, Stanford, CA 94305-5623, USA. glaport@stanford.edu

Current Hematology Reports

|August 7, 2003

Summary

Nonmyeloablative stem cell transplantation (NMSCT) offers a safer alternative to traditional chemotherapy and radiotherapy in allogeneic stem cell transplantation (ASCT). This approach shows promise for hematologic malignancies by enabling graft-versus-leukemia effects for disease eradication.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial.

The Journal of experimental medicine·2020

Same author

Infusion of donor-derived CD8<sup>+</sup> memory T cells for relapse following allogeneic hematopoietic cell transplantation.

Blood advances·2018

Same author

HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity.

Blood advances·2018

Same author

Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703).

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation·2018

Same author

CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation·2016

Same author

Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation·2016

Area of Science:

Hematology
Oncology
Immunology

Background:

Traditional allogeneic stem cell transplantation (ASCT) uses high-dose chemoradiotherapy, leading to significant toxicities.
Less intensive conditioning regimens are being explored to improve ASCT safety.
Nonmyeloablative stem cell transplantation (NMSCT) has emerged as a promising development for hematologic malignancies.

Purpose of the Study:

To review the background and rationale for nonmyeloablative stem cell transplantation (NMSCT).
To discuss the impact of NMSCT on treating patients with acute leukemia.

Main Methods:

NMSCT utilizes immunosuppressive doses of chemotherapy and radiotherapy.
This regimen aims to establish a mixed donor-host hematopoietic chimeric state.

Related Experiment Videos

It relies on a donor immune-mediated graft-versus-leukemia effect for disease control.

Main Results:

Early studies of NMSCT have shown encouraging results.
High engraftment rates have been observed.
Sustained remissions have been achieved in patients with hematologic malignancies.

Conclusions:

NMSCT represents a significant advancement in treating hematologic malignancies.
It offers a potentially safer alternative to conventional ASCT.
The graft-versus-leukemia effect is the primary mechanism for disease eradication in NMSCT.